Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

45.6  +0.61 (+1.36%)

After market: 45.6 0 (0%)

Fundamental Rating

4

Taking everything into account, EXAS scores 4 out of 10 in our fundamental rating. EXAS was compared to 550 industry peers in the Biotechnology industry. The financial health of EXAS is average, but there are quite some concerns on its profitability. EXAS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EXAS has reported negative net income.
In the past year EXAS had a positive cash flow from operations.
In the past 5 years EXAS always reported negative net income.
In multiple years EXAS reported negative operating cash flow during the last 5 years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

With a decent Return On Assets value of -17.34%, EXAS is doing good in the industry, outperforming 79.45% of the companies in the same industry.
The Return On Equity of EXAS (-40.71%) is better than 70.36% of its industry peers.
Industry RankSector Rank
ROA -17.34%
ROE -40.71%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

EXAS has a better Gross Margin (68.19%) than 81.09% of its industry peers.
EXAS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EXAS has more shares outstanding
EXAS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EXAS is higher compared to a year ago.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

EXAS has an Altman-Z score of 1.04. This is a bad value and indicates that EXAS is not financially healthy and even has some risk of bankruptcy.
EXAS's Altman-Z score of 1.04 is fine compared to the rest of the industry. EXAS outperforms 65.82% of its industry peers.
EXAS has a debt to FCF ratio of 18.77. This is a negative value and a sign of low solvency as EXAS would need 18.77 years to pay back of all of its debts.
The Debt to FCF ratio of EXAS (18.77) is better than 91.64% of its industry peers.
A Debt/Equity ratio of 0.94 indicates that EXAS is somewhat dependend on debt financing.
The Debt to Equity ratio of EXAS (0.94) is worse than 77.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF 18.77
Altman-Z 1.04
ROIC/WACCN/A
WACC8.79%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 2.89 indicates that EXAS has no problem at all paying its short term obligations.
With a Current ratio value of 2.89, EXAS is not doing good in the industry: 66.18% of the companies in the same industry are doing better.
A Quick Ratio of 2.56 indicates that EXAS has no problem at all paying its short term obligations.
With a Quick ratio value of 2.56, EXAS is not doing good in the industry: 68.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.56
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

EXAS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -465.63%.
Looking at the last year, EXAS shows a quite strong growth in Revenue. The Revenue has grown by 12.56% in the last year.
EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.78% yearly.
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%

3.2 Future

Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 22.14% on average per year.
Based on estimates for the next years, EXAS will show a quite strong growth in Revenue. The Revenue will grow by 10.21% on average per year.
EPS Next Y86.15%
EPS Next 2Y42.89%
EPS Next 3Y29.66%
EPS Next 5Y22.14%
Revenue Next Year12.85%
Revenue Next 2Y12.78%
Revenue Next 3Y12.49%
Revenue Next 5Y10.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 196.35 indicates a quite expensive valuation of EXAS.
87.82% of the companies in the same industry are more expensive than EXAS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.34, EXAS is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 196.35
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

90.73% of the companies in the same industry are more expensive than EXAS, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, EXAS is valued cheaper than 92.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 69.03
EV/EBITDA 146.95
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
EXAS's earnings are expected to grow with 29.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.89%
EPS Next 3Y29.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXAS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXACT SCIENCES CORP

NASDAQ:EXAS (8/15/2025, 8:17:59 PM)

After market: 45.6 0 (0%)

45.6

+0.61 (+1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners98.76%
Inst Owner Change1.54%
Ins Owners0.87%
Ins Owner Change5.97%
Market Cap8.60B
Analysts85.45
Price Target70.38 (54.34%)
Short Float %4.01%
Short Ratio2.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.88%
Min EPS beat(2)-39.07%
Max EPS beat(2)94.84%
EPS beat(4)2
Avg EPS beat(4)-333.8%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.84%
EPS beat(8)5
Avg EPS beat(8)-143.34%
EPS beat(12)9
Avg EPS beat(12)-87.36%
EPS beat(16)11
Avg EPS beat(16)-65.58%
Revenue beat(2)2
Avg Revenue beat(2)1.64%
Min Revenue beat(2)0.62%
Max Revenue beat(2)2.65%
Revenue beat(4)2
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)2.65%
Revenue beat(8)2
Avg Revenue beat(8)-0.26%
Revenue beat(12)6
Avg Revenue beat(12)1.07%
Revenue beat(16)10
Avg Revenue beat(16)1.66%
PT rev (1m)-0.48%
PT rev (3m)-0.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-60.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 196.35
P/S 2.93
P/FCF 69.03
P/OCF 28.15
P/B 3.48
P/tB N/A
EV/EBITDA 146.95
EPS(TTM)-5.43
EYN/A
EPS(NY)0.23
Fwd EY0.51%
FCF(TTM)0.66
FCFY1.45%
OCF(TTM)1.62
OCFY3.55%
SpS15.58
BVpS13.09
TBVpS-4.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.34%
ROE -40.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.19%
FCFM 4.24%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF 18.77
Debt/EBITDA 35.11
Cap/Depr 83.3%
Cap/Sales 6.16%
Interest Coverage N/A
Cash Conversion 459.82%
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.56
Altman-Z 1.04
F-Score4
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
EPS Next Y86.15%
EPS Next 2Y42.89%
EPS Next 3Y29.66%
EPS Next 5Y22.14%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%
Revenue Next Year12.85%
Revenue Next 2Y12.78%
Revenue Next 3Y12.49%
Revenue Next 5Y10.21%
EBIT growth 1Y16.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year321.21%
EBIT Next 3Y82.67%
EBIT Next 5Y50.87%
FCF growth 1Y214.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y316.93%
OCF growth 3YN/A
OCF growth 5YN/A